Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25112010 | 0.73 | CYP2C9 (0.39) | CYP2D6ALDH1A1 | |
| SCHEMBL22783579 | 0.72 | CYP2C9 (0.47) | CYP2D6ALDH1A1 | |
| SCHEMBL24533356 | 0.72 | CYP2C9 (0.46) | CYP2D6ALDH1A1 | |
| SCHEMBL17953054 | 0.67 | CYP3A4 (0.61) | CYP2D6ALDH1A1 | |
| SCHEMBL16618521 | 0.67 | CYP3A4 (0.61) | CYP2D6ALDH1A1 | |
| SCHEMBL22783548 | 0.66 | CYP3A4 (0.48) | CYP2D6 | |
| SCHEMBL25112185 | 0.66 | CYP3A4 (0.48) | CYP2D6 | |
| SCHEMBL17953051 | 0.64 | CHRNA4 (0.50) | — | |
| SCHEMBL17953052 | 0.63 | NR1H2 (0.45) | — | |
| SCHEMBL1463716 | 0.60 | CHRNA4 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | CYP2D6 1815/4885ALDH1A1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.